Southpoint sells Fennec Pharmaceuticals (FENC) shares worth $636k
PositiveFinancial Markets

Southpoint has successfully sold shares of Fennec Pharmaceuticals worth $636,000, marking a significant financial move for the investment firm. This sale not only reflects Southpoint's strategic approach to managing its portfolio but also highlights the growing interest in Fennec Pharmaceuticals, a company focused on innovative treatments. Such transactions are crucial as they can influence market dynamics and investor confidence in the pharmaceutical sector.
— Curated by the World Pulse Now AI Editorial System